Highlights and Quick Summary
- SG&A Expenses for the quarter ending February 28, 2023 was $12.8 Million (a -1.01% decrease compared to previous quarter)
- Year-over-year quarterly SG&A Expenses decreased by -10.55%
- Annual SG&A Expenses for 2022 was $50.7 Million (a 22.29% increase from previous year)
- Annual SG&A Expenses for 2021 was $41.5 Million (a 13.21% increase from previous year)
- Annual SG&A Expenses for 2020 was $36.6 Million (a 14.64% increase from previous year)
- Twelve month SG&A Expenses ending February 28, 2023 was $54.2 Million (a 2.17% increase compared to previous quarter)
- Twelve month trailing SG&A Expenses increased by 12.02% year-over-year
Trailing SG&A Expenses for the last four month:
28 Feb '23 | 30 Nov '22 | 31 Aug '22 | 31 May '22 |
---|---|---|---|
$54.2 Million | $53.1 Million | $50.7 Million | $48.4 Million |
Visit stockrow.com/OGI
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical SG&A Expenses of Organigram Holdings Inc.
Most recent SG&A Expensesof OGI including historical data for past 10 years.Interactive Chart of SG&A Expenses of Organigram Holdings Inc.
Organigram Holdings Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2023 | $12.82 | – | – | – | – |
2022 | $12.95 | $14.12 | $14.33 | $11.67 | $50.72 |
2021 | $10.6 | $11.8 | $11.44 | $9.48 | $41.48 |
2020 | $8.76 | $8.54 | $8.12 | $11.62 | $36.64 |
2019 | $8.35 | $12.17 | $8.29 | $7.3 | $31.96 |
2018 | – | – | – | $4.2 | $12.59 |
2017 | – | – | – | – | $5.82 |
2016 | – | – | – | – | $3.11 |
Business Profile of Organigram Holdings Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic